Skip to main content

Company profile

Cellectar Biosciences, Inc.

Pipeline3 assets

Iopofosine I 131CLR 131 / tumor cells via phospholipid drug conjugate delivery / PDC radiotherapeutic; iodine-131 beta emitter / Oncology
Relapsed/refractory Waldenström macroglobulinemiaPhase 2 pivotalcompletedRelapsed/refractory multiple myelomaPhase 2bongoingCNS lymphomaPhase 2bongoing
CLR 121125CLR 125 / tumor cell nucleus via phospholipid ether platform / PLE radioconjugate; iodine-125 Auger emitter / Oncology
Relapsed/refractory triple-negative breast cancerPhase 1bongoing
CLR 121225CLR 225 / tumor cells via phospholipid ether platform / PLE radioconjugate; actinium-225 alpha emitter / Oncology
Pancreatic cancerPhase 1planned

Latest news11 items

Sep 29, 2026

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia

Presentation / Abstract • Phase 2Poster presentation Thu, Oct 15, 2026, 4:00 PM

Aug 13, 2026

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Presentation / Abstract • Phase 2

Jul 30, 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Jul 15, 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Jun 1, 2026

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Presentation / Abstract • Phase 2ASCO poster presentation Mon, Jun 1, 2026, 9:00 AM CDT

May 14, 2026

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Presentation / Abstract • Phase 2ASCO poster presentation Mon, Jun 1, 2026, 9:00 AM CDT

May 11, 2026

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

May 5, 2026

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

Trial Results • Phase 2

May 5, 2026

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

Apr 21, 2026

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Presentation / Abstract • Phase 2

Apr 14, 2026

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

Trial Start • Phase 1

Cellectar Biosciences, Inc. • Endpoint Arena